Latest Conference Articles

Dr Lee Schwartzberg Discusses Immunotherapy Approvals in TNBC

Dr Lee Schwartzberg Discusses Immunotherapy Approvals in TNBC

December 10th 2020, 11:45am

San Antonio Breast Cancer Symposium

Lee Schwartzberg, MD, FACP, chief medical director of West Cancer Center and chief medical officer of OneOncology, discusses the approvals of pembrolizumab and sacituzumab govitecan for patients with triple-negative breast cancer.

A Look at Established, Emerging Biomarkers for I-O Therapy in Breast Cancer

A Look at Established, Emerging Biomarkers for I-O Therapy in Breast Cancer

December 10th 2020, 2:45am

San Antonio Breast Cancer Symposium

During the San Antonio Breast Cancer Symposium 2020, Lajos Pusztai, MD, DPhil, of Yale Cancer Center, reviewed recently established and emerging biomarkers in both the neoadjuvant and metastatic breast cancer settings.

Dr Yuan Yuan on Oral Ipatasertib's Potential in mTNB

Dr Yuan Yuan on Oral Ipatasertib's Potential in mTNB

December 9th 2020, 9:00pm

San Antonio Breast Cancer Symposium

Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.

Dr Joanne Mortimer Discusses Novel Oral SERD ZN-c5 in ER-Positive Breast Cancer

Dr Joanne Mortimer Discusses Novel Oral SERD ZN-c5 in ER-Positive Breast Cancer

December 9th 2020, 2:00pm

San Antonio Breast Cancer Symposium

City of Hope's Joanne Mortimer, MD, a medical oncologist and director of the Women's Cancer Program, discusses a poster presentation from the 2020 San Antonio Breast Cancer Symposium.

2020 Brings 3 Drugs: How the Breast Cancer Treatment Landscape Has Evolved

2020 Brings 3 Drugs: How the Breast Cancer Treatment Landscape Has Evolved

December 9th 2020, 1:30pm

San Antonio Breast Cancer Symposium

A panel at the 2020 San Antonio Breast Cancer Symposium discussed 3 new drug approvals from the past year, highlighting changes in the treatment landscape across multiple breast cancer types.

Dr Rachel Jimenez: Risk, Nature of Cardiac Toxicity in Breast Cancer Is Variable

Dr Rachel Jimenez: Risk, Nature of Cardiac Toxicity in Breast Cancer Is Variable

December 8th 2020, 11:00pm

San Antonio Breast Cancer Symposium

Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.

The Role of Race, Ethnicity, and Cancer in the Time of COVID-19

The Role of Race, Ethnicity, and Cancer in the Time of COVID-19

December 8th 2020, 9:15pm

San Antonio Breast Cancer Symposium

The first session at the San Antonio Breast Cancer Symposium 2020 looked at how the COVID-19 pandemic is disproportionately affecting care for minority patients.

Dr Karl Kilgore: Updated Data Suggest CAR T Costs, Adverse Events Are Decreasing

Dr Karl Kilgore: Updated Data Suggest CAR T Costs, Adverse Events Are Decreasing

December 8th 2020, 3:23pm

ASH: American Society of Hematology

As more data have become available, we are seeing more and more patients receiving chimeric antigen receptor (CAR) T-cell therapy in the community setting, noted Karl Kilgore, PhD, senior research scientist at Avalere Health.

Genetic Tracing Finds Mutations for Blood Cancer Appear Decades Before Diagnosis

Genetic Tracing Finds Mutations for Blood Cancer Appear Decades Before Diagnosis

December 8th 2020, 3:00pm

ASH: American Society of Hematology

A late-breaking study presented at the American Society of Hematology annual meeting raises the specter of whether interventions can occur decades before a blood cancer would appear.

Zanubrutinib Studies Highlight Efficacy, Tolerability in MZL, CLL, SLL

Zanubrutinib Studies Highlight Efficacy, Tolerability in MZL, CLL, SLL

December 8th 2020, 4:45am

ASH: American Society of Hematology

The treatment appeared to live up to its billing of having fewer off-target effects in studies presented at the American Society of Hematology.